Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups

AIDS

Volumn 11, Issue 4, 1997, Pages 461-467

  Dorrucci, Maria ^a   Pezzotti, Patrizio ^a   Phillips, Andrew N ^b   Alliegro, Maria B ^a   Rezza, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antiretroviral therapy; HIV exposure groups; Progression to AIDS

Indexed keywords

ANTIVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; ITALY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; STATISTICAL MODEL;

EID: 0031048968     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199704000-00009     Document Type: Article

References (25)

1. Fischl MA, Richman DD, Grieco MH, et al.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex: a double-blind placebo controlled trial. N Engl J Med 1987, 317:185-191.
2. Fischl MA, Richman DD, Hansen N, et al.: The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. Ann Intern Med 1990, 112:727-737.
3. Volberding PA, Lagakos SW, Koch MA, et al.: Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990, 322:941-949.
4. Mulder JW, Cooper DA, Mathiesen L, et al.: Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized double-blind placebo-controlled study. AIDS 1994, 8:313-321.
5. Cooper DA, Gatell JM, Kroon S: Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter.N Engl J Med 1993, 329:297-303.
6. Egger M, Neaton JD, Phillips AN, Davey Smith G: Concorde trial of immediate versus deferred zidovudine [letter]. Lancet 1994, 343:1355.
7. Concorde Coordinating Committee: Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994, 343:871-881.
8. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696-699.
9. Eron JJ, Benoit SL, Jemsek J, et al.: Treatment with lamiduvine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662-1669.
10. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimiter. N Engl J Med 1996, 335:1081-1090.
11. Delta Coordinating Committee: Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals, Lancet 1996, 348:273-278.
12. Graham NHM, Zeger SL, Park LP: Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression to HIV-1 infection to AIDS. Lancet 1991, 328:265-269.
13. Longini IM, Clark WS, Karon JM: Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population based cohort. Am J Epidemiol 1993, 137:1229-1240.
14. Graham NMH, Zeger SL, Park IP, et al.: The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med 1992, 326:1037-1042.
15. The Italian Seroconversion Study: Disease progression and early predictors of AIDS in HIV-seroconverted injecting drug users. AIDS 1992, 6:421-429.
16. Centers for Disease Control: Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.
17. Lee ET: Statistical Methods for Survival Data Analysis. New York: John Wiley & Sons; 1992.
18. Phillips AN, Lee CA, Elford J, Janossy G, Kernoff PBA: The cumulative risk of AIDS as the CD4+ lymphocytes count declines. J Acquir Immune Defic Syndr 1992, 5:148-152.
19. Byar DP, Schoenfeld DA, Green SB, et al.: Design considerations for AIDS trials. N Engl J Med 1990, 323:1343-1348.
20. Lundgren JD, Phillips AN, Pedersen C, et al.: Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA 1994, 271:1088-1092.
21. Stein MD, Piette J, Mor V, et al.: Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med 1991, 6:35-40.
22. Rosenberg PS, Gail MH, Schrager LK, et al.: National AIDS incidence trends and the extent of zidovudine therapy in selected demographic and transmission groups. J Acquir Immune Defic Syndr 1991, 4:393-401.
23. Easterbrook PJ, Keruly JC, Creagh Kirk T, Richman DD, Chaisson RE, Moore RD: Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease: zidovudine epidemiology study group. JAMA 1991, 266:2713-2718.
24. Broers B, Morabia A, Hirschel B: A cohort study of drug users' compliance with zidovudine treatment. Arch Intern Med 1994, 154:1121-1127.
25. Volberding PA, Lagakos SW, Grimes JM, et al.: A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. N Engl J Med 1995, 333:401-407.